U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Maple Rose Enterprises, Inc, dba Pencol Pharmacy - 520095 - 03/10/2022
  1. Warning Letters

CLOSEOUT LETTER

Maple Rose Enterprises, Inc, dba Pencol Pharmacy MARCS-CMS 520095 —

Delivery Method:
VIA EMAIL CONFIRMED DELIVERY
Product:
Drugs
Recipient:
Recipient Name
Mr. Tony E. Jones
Recipient Title
Owner
Maple Rose Enterprises, Inc, dba Pencol Pharmacy

1325 S. Colorado Blvd
Suite B-024
Denver, CO 80222
United States

Issuing Office:
Los Angeles District Office

United States

Dear Mr. Jones:

The U.S. Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our warning letter (Ref CMS 520095) dated August 2, 2017. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
Lance M. De Souza
Acting Director, Pharmaceutical Quality Operations IV

Back to Top